Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine plus sufentanil PCIA versus sufentanil PCIA after open surgery
ChiCTR1800020059Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine and sufentanil in postoperative pain (2 arms), sponsored by Xijing Hospital. Primary endpoints: NRS resting pain score and NRS active pain score. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
nalbuphinesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR1800020059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020059.